Tan Thanh Holdings

Tan Thanh Holdings, one of the fastest-growing pharmaceutical enterprises in the ASEAN region, has received approval from Vietnam's Ministry of Health to conduct late-stage clinical trials for Oravax's oral COVID-19 vaccine and will contribute to funding and implementing clinical development and regulatory approval. The ASEAN region spends nearly 4% of its GDP on healthcare, with a pharmaceutical industry valued at $25 billion, and is expected to continue growing.